Dr. Elizabeth Barrows is a triple board-certified medical oncologist specializing in breast cancer care and clinical research. She treats patients across all stages of breast cancer, including hormone receptor-positive, HER2-positive, and triple negative disease, with expertise in chemotherapy, targeted therapies, immunotherapy, and precision medicine. Dr. Barrows is committed to advancing patient-centered cancer care and encouraging participation in clinical trials to expand treatment options and improve outcomes. She earned her medical degree from The George Washington University School of Medicine and completed her residency at MedStar Georgetown University Hospital and fellowship training in Hematology/Oncology at Georgetown Lombardi Comprehensive Cancer Center.
Dr. Barrows is an active member of leading national and international oncology organizations, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and multiple NRG Oncology committees focused on medical oncology, breast oncology, and developmental therapeutics. Her academic and clinical contributions have been recognized through several honors, including the Lynn Sage Breast Cancer Symposium Travel Award, the Edward Tsou MD Medical Humanities Award for compassionate patient care, and distinctions for academic excellence and research achievement. She continues to advance her leadership and expertise through professional development opportunities, including participation in the 2024 ARTES Leadership Course.
Research Interests
Her research interests focus on advancing innovative treatment strategies for breast cancer, with an emphasis on treatment-resistant disease, clinical trials, and improving patient outcomes.
Selected Research
2023 - ASTX727 in combination with cemiplimab and fianlimab in advanced endocrine refractory HR+/HER2- and triple negative metastatic breast cancer
Role: Principal investigator, trial design and development
Mentor: Harry D. Bear, MD, PhD
2024 - Site PI, A2A-O-004: First-In-Human, Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study evaluating AO-252, A Protein-Protein inhibitor of TACC3, in advanced solid tumors including triple negative breast cancer (TNBC), high grade serous ovarian carcinoma (HGSOC) and endometrial cancer
2024 - Role of Breast Cancer Index (BCI) in clinical decision-making for extended endocrine therapy in HR+/HER2- early-stage breast cancer
Role: Principal investigator, trial design and development
Mentor: Kandace McGuire, MD
Research Areas
- Maternal-Fetal/Women’s HealthOncology